Manufacturer
Merck Healthcare KGaA(GERMANY)
Registraction Number
MAL24126005AZ
Content:
Each film-coated tablet contains:
-Tepotinib (as hydrochloride hydrate): 225 mg
Indications:
Non-Small Cell Lung Cancer (NSCLC): Used for the treatment of adult patients with metastatic non-small cell lung cancer harboring mesenchymal-epithelial transition (MET) exon 14 skipping alterations2.
Instructions:
Dosage: The recommended dose is 450 mg (two 225 mg tablets) taken orally once daily with food until disease progression or unacceptable toxicity3.
Administration: Swallow the tablets whole with water. Do not chew, crush, or split the tablets. If a dose is missed, it can be taken as soon as remembered on the same day, unless the next dose is due within 8 hours.
Malaysia
